This is now and always has been a high risk/high reward

New Post Public Reply Private Reply Replies (1) Message Board
AlanC Tmacarthur #91134
561
This is now and always has been a high risk/high reward investment. Companies like NTEK go public to raise capital by selling stock to risk taking investors like you and I. The risk is high for all new companies but for those trading on the OTC it is even higher because you immediatly attract those that want to bankrupt the company by selling "air" shares. Those doing this include hedge funds, investment banks and some of the largest companies in the world who would quickly deny any knowledge that they were participants were they to be exposed. These groups employ folks to post fear, uncertainty and doubt while attacking both the company and its Officers and Directors. They are often sucessful in bankrupting companies they are attacking by eliminating the value of shares.Sometimes however it backfires and those once worthless shares become very valuable and those that sold em are forced to buy them back resulting in huge gains for those that own them and huge losses for those that sold them. The huge naked short may well be NTEK's most valuable asset at the moment if David is able to turn the tables on those trying to destroy the company. We all know David is a tech genius and most longs like myself are hoping he succeeds.
With some luck that 99% loss could turn into a many thousands percent gain. This group of friends and supporters are hoping for that outcome.
Go NTEK!!!

Nanotech Entertainment Inc. (NTEK) Stock Research Links

NTEK Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Lumexa Imaging's Investor Conference Push: Any Real Substance?

Updated Category News Views 132

Lumexa Imaging just dropped a line on Feb 17, 2026, about their upcoming investor conference gigs. Sure, they're strutting into multiple events—Raymond James in Orlando, Leerink Partners in Miami, and Barclays back-to-back days after that. But here’s the kicker: are these talks really worth the buzz? In a space where outpatient imaging claims to be kingpin, you’ve...

Continue Reading
Current Landscape of US Stock Futures Amid Rate Cuts

Updated Category News Views 173

Insights on the Current Stability of U.S. Stock Futures During Asian trading hours, U.S. stock index futures have held steady. Investors are hoping for interest rate cuts as the Federal Reserve's next meeting approaches. This meeting is expected to reveal a significant easing cycle that many in the market are eagerly anticipating. Even with strong reports on consumer and...

Continue Reading
Wispr Flow Revolutionizes Voice Dictation Across Platforms

Updated Category News Views 469

Wispr Flow Expands Its Reach in Voice Dictation Technology In a world where speed and efficiency are paramount, Wispr, known as The Voice Interface Company, is revolutionizing the way we interact with technology. With the recent launch of Wispr Flow for Windows, this innovative voice productivity tool is now accessible to users across both Mac and Windows platforms,...

Continue Reading
MintMiner: Your Ultimate Gateway to Cloud Mining Success

Updated Category News Views 197

Unlocking the Future of Cloud Mining with MintMiner In today's uncertain financial landscape, MintMiner presents an innovative solution for anyone looking to tap into the world of digital assets. As global financial systems face challenges, MintMiner offers a unique platform that makes cloud mining accessible, straightforward, and profitable. Understanding Cloud Mining...

Continue Reading
GT Biopharma's Strategic Move: Withdrawal of S-1 Registration

Updated Category News Views 100

GT Biopharma's Strategic Withdrawal of Form S-1 Registration GT Biopharma, Inc. (NASDAQ: GTBP) recently made headlines with its request for withdrawal of a Form S-1 registration statement. This decision marks a crucial moment for the company, based in San Francisco, known for its innovative approach in the immuno-oncology sector. GT Biopharma focuses on the development of...

Continue Reading